Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA advisory committee delays review of Bexxar

Jan. 14, 2002

Genta files IND for gallium nitrate in NHL

Jan. 11, 2002

Onyvax initiates phase II trial of Onyvax P in prostate cancer

Jan. 11, 2002

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

Jan. 10, 2002

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

Jan. 10, 2002

Antisense oligonucleotide targeting Ki-ras as an approach to colorectal cancer

Jan. 10, 2002

Endothelial cell-specific inhibition of protein synthesis demonstrated for tumstatin

Jan. 10, 2002

Prescient NeuroPharma licenses anhydrovinblastine to Access Oncology

Jan. 10, 2002

Study protocol changes following early positive results for Gleevec in CML

Jan. 9, 2002

Idec's BLA for Zevalin radioimmunotherapy approvable according to FDA

Jan. 9, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...